Revelation Biosciences REVB
NASDAQ REVB
$0.77 -0.03 (-3.75%)
At close: Oct 2, 2026 · 4:00 PM EDT

Revelation Biosciences (REVB) Other Accumulated Expenses (2021)

Updated

Revelation Biosciences' Other Accumulated Expenses was $1.54 million in Q4 2021, up 19.7% from the prior quarter.

Analysis

Revelation Biosciences (REVB) Other Accumulated Expenses (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Revelation Biosciences 3.01 Mn -46.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 1.54 Mn
Sep 30, 2021 1.28 Mn
Jun 30, 2021 140,459.00
API Access

Revelation Biosciences Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=REVB&period=max&api_key=YOUR_API_KEY